Persistencia de síntomas de enfermedad por reflujo gastroesofágico en pacientes tratados con inhibidores de bomba de protones Estudio observacional.
Saved in:
| Title: | Persistencia de síntomas de enfermedad por reflujo gastroesofágico en pacientes tratados con inhibidores de bomba de protones Estudio observacional. |
|---|---|
| Alternate Title: | Persistent gastroesophageal reflux disease symptoms in patients treated with proton pump inhibitors An observational study. |
| Authors: | Alvarez-Quintero, Patricia Eugenia1, Vallejos-Narváez, Álvaro2, Castro-Osman, Gloria Esperanza2, Díaz-Portilla • Bogotá, Andrés David2 |
| Source: | Acta Medica Colombiana. ene-mar2026, Vol. 51 Issue 1, p1-11. 11p. |
| Subjects: | PROTON pump inhibitors, SYMPTOMS, HEARTBURN, GASTROESOPHAGEAL reflux, PATIENT compliance, ESOMEPRAZOLE |
| Geographic Terms: | COLOMBIA |
| Abstract (English): | Introduction: gastroesophageal reflux disease (GERD) has a high prevalence, affecting quality of life and generating high healthcare costs. Although proton pump inhibitors (PPIs) are the main treatment, up to 55% of patients have persistent symptoms. Objective: to determine the prevalence of persistent GERD symptoms in patients with current or recent PPI treatment. Method: a descriptive, cross-sectional observational study of 434 patients over the age of 18 with a prior GERD diagnosis who were seen as outpatients by a panel of selected physicians in Colombia. Symptom persistence and/or relapse was evaluated, and sociodemographic and clinical variables were analyzed through descriptive statistics and bivariate analyses. Results: 94.5% of patients reported at least one GERD symptom in the previous seven days, with heartburn (75.8%) and reflux (74.2%) being the most frequent. There were fewer symptoms among patients who took PPIs in the morning and before meals. Dexlansoprazole and esomeprazole were associated with a lower frequency of symptoms, compared to other PPIs. Conclusion: the high persistence of symptoms despite PPI use exceeds the international figures, which could reflect differences in adherence to treatment, genetic factors or cultural behaviors in the Colombian population. The variable effectiveness between PPIs underscores the need to individualize treatment, optimize dosing, and educate on correct treatment administration. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Introducción: la enfermedad por reflujo gastroesofágico (ERGE) tiene alta prevalencia, impactando la calidad de vida y generando altos costos en salud. Aunque los inhibidores de bomba de protones (IBP) son el tratamiento principal, hasta 55% de los pacientes mantiene síntomas persistentes. Objetivo: determinar la prevalencia de persistencia de síntomas de ERGE en pacientes con tratamiento actual o reciente con IBP. Metodología: estudio observacional descriptivo de corte transversal en 434 pacientes mayores de 18 años con diagnóstico previo de ERGE que asistieron a consulta ambulatoria en un panel de médicos seleccionados en Colombia. Se evaluó la persistencia y/o recaída de síntomas, y se analizaron variables sociodemográficas y clínicas mediante estadística descriptiva y análisis bivariado. Resultados: el 94.5% de los pacientes reportaron al menos un síntoma relacionado con ERGE en los últimos siete días, siendo la pirosis (75.8%) y la regurgitación (74.2%) los síntomas más frecuentes. Se observó una menor proporción de síntomas en pacientes que tomaron IBP en la mañana y antes de una comida. El dexlansoprazol y esomeprazol se relacionaron con una menor frecuencia de síntomas en comparación con otros IBP. Conclusión: la alta persistencia de síntomas a pesar del uso de IBP supera cifras internacionales, lo que podría reflejar diferencias en el método utilizado para el diagnóstico de ERGE, la adherencia al tratamiento, factores genéticos o comportamientos culturales en la población colombiana. Las diferencias en efectividad entre IBP resaltan la necesidad de personalizar tratamientos, optimizar pautas posológicas y educar sobre su administración correcta del tratamiento. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Medica Colombiana is the property of Acta Medica Colombiana and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 192644297 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Persistencia de síntomas de enfermedad por reflujo gastroesofágico en pacientes tratados con inhibidores de bomba de protones Estudio observacional. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Persistent gastroesophageal reflux disease symptoms in patients treated with proton pump inhibitors An observational study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Alvarez-Quintero%2C+Patricia+Eugenia%22">Alvarez-Quintero, Patricia Eugenia</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Vallejos-Narváez%2C+Álvaro%22">Vallejos-Narváez, Álvaro</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Castro-Osman%2C+Gloria+Esperanza%22">Castro-Osman, Gloria Esperanza</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Díaz-Portilla+•+Bogotá%2C+Andrés+David%22">Díaz-Portilla • Bogotá, Andrés David</searchLink><relatesTo>2</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Acta+Medica+Colombiana%22">Acta Medica Colombiana</searchLink>. ene-mar2026, Vol. 51 Issue 1, p1-11. 11p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22PROTON+pump+inhibitors%22">PROTON pump inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22SYMPTOMS%22">SYMPTOMS</searchLink><br /><searchLink fieldCode="DE" term="%22HEARTBURN%22">HEARTBURN</searchLink><br /><searchLink fieldCode="DE" term="%22GASTROESOPHAGEAL+reflux%22">GASTROESOPHAGEAL reflux</searchLink><br /><searchLink fieldCode="DE" term="%22PATIENT+compliance%22">PATIENT compliance</searchLink><br /><searchLink fieldCode="DE" term="%22ESOMEPRAZOLE%22">ESOMEPRAZOLE</searchLink> – Name: SubjectGeographic Label: Geographic Terms Group: Su Data: <searchLink fieldCode="DE" term="%22COLOMBIA%22">COLOMBIA</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Introduction: gastroesophageal reflux disease (GERD) has a high prevalence, affecting quality of life and generating high healthcare costs. Although proton pump inhibitors (PPIs) are the main treatment, up to 55% of patients have persistent symptoms. Objective: to determine the prevalence of persistent GERD symptoms in patients with current or recent PPI treatment. Method: a descriptive, cross-sectional observational study of 434 patients over the age of 18 with a prior GERD diagnosis who were seen as outpatients by a panel of selected physicians in Colombia. Symptom persistence and/or relapse was evaluated, and sociodemographic and clinical variables were analyzed through descriptive statistics and bivariate analyses. Results: 94.5% of patients reported at least one GERD symptom in the previous seven days, with heartburn (75.8%) and reflux (74.2%) being the most frequent. There were fewer symptoms among patients who took PPIs in the morning and before meals. Dexlansoprazole and esomeprazole were associated with a lower frequency of symptoms, compared to other PPIs. Conclusion: the high persistence of symptoms despite PPI use exceeds the international figures, which could reflect differences in adherence to treatment, genetic factors or cultural behaviors in the Colombian population. The variable effectiveness between PPIs underscores the need to individualize treatment, optimize dosing, and educate on correct treatment administration. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Introducción: la enfermedad por reflujo gastroesofágico (ERGE) tiene alta prevalencia, impactando la calidad de vida y generando altos costos en salud. Aunque los inhibidores de bomba de protones (IBP) son el tratamiento principal, hasta 55% de los pacientes mantiene síntomas persistentes. Objetivo: determinar la prevalencia de persistencia de síntomas de ERGE en pacientes con tratamiento actual o reciente con IBP. Metodología: estudio observacional descriptivo de corte transversal en 434 pacientes mayores de 18 años con diagnóstico previo de ERGE que asistieron a consulta ambulatoria en un panel de médicos seleccionados en Colombia. Se evaluó la persistencia y/o recaída de síntomas, y se analizaron variables sociodemográficas y clínicas mediante estadística descriptiva y análisis bivariado. Resultados: el 94.5% de los pacientes reportaron al menos un síntoma relacionado con ERGE en los últimos siete días, siendo la pirosis (75.8%) y la regurgitación (74.2%) los síntomas más frecuentes. Se observó una menor proporción de síntomas en pacientes que tomaron IBP en la mañana y antes de una comida. El dexlansoprazol y esomeprazol se relacionaron con una menor frecuencia de síntomas en comparación con otros IBP. Conclusión: la alta persistencia de síntomas a pesar del uso de IBP supera cifras internacionales, lo que podría reflejar diferencias en el método utilizado para el diagnóstico de ERGE, la adherencia al tratamiento, factores genéticos o comportamientos culturales en la población colombiana. Las diferencias en efectividad entre IBP resaltan la necesidad de personalizar tratamientos, optimizar pautas posológicas y educar sobre su administración correcta del tratamiento. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Acta Medica Colombiana is the property of Acta Medica Colombiana and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=192644297 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.36104/amc.2026.4754 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 11 StartPage: 1 Subjects: – SubjectFull: PROTON pump inhibitors Type: general – SubjectFull: SYMPTOMS Type: general – SubjectFull: HEARTBURN Type: general – SubjectFull: GASTROESOPHAGEAL reflux Type: general – SubjectFull: PATIENT compliance Type: general – SubjectFull: ESOMEPRAZOLE Type: general – SubjectFull: COLOMBIA Type: general Titles: – TitleFull: Persistencia de síntomas de enfermedad por reflujo gastroesofágico en pacientes tratados con inhibidores de bomba de protones Estudio observacional. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Alvarez-Quintero, Patricia Eugenia – PersonEntity: Name: NameFull: Vallejos-Narváez, Álvaro – PersonEntity: Name: NameFull: Castro-Osman, Gloria Esperanza – PersonEntity: Name: NameFull: Díaz-Portilla • Bogotá, Andrés David IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: ene-mar2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 01202448 Numbering: – Type: volume Value: 51 – Type: issue Value: 1 Titles: – TitleFull: Acta Medica Colombiana Type: main |
| ResultId | 1 |
